Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.
- Conditions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 100
- Registration Number
- NCT05975320
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Peshawar Institute of Cardiology
- Target Recruit Count
- 141
- Registration Number
- NCT05973188
- Locations
- 🇵🇰
Peshawar Institute of Cardiology, Peshawar, KPK, Pakistan
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT05891119
- Locations
- 🇺🇸
Direct Helpers Research Center (DHRC), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States
🇺🇸DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05815680
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13945
- Registration Number
- NCT05795062
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Anticoagulation in Post MI LV Thrombus Trial in Nepal
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shahid Gangalal National Heart Centre
- Target Recruit Count
- 196
- Registration Number
- NCT05794399
- Locations
- 🇳🇵
Nepal Health Research Council, Kathmandu, Bagmati, Nepal
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-08-07
- Target Recruit Count
- 202
- Registration Number
- NCT05782270
- Locations
- 🇨🇳
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741385
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-04-07
- Target Recruit Count
- 50
- Registration Number
- NCT05705089
- Locations
- 🇮🇷
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of
🇮🇷Tehran Heart Center, Tehran, Iran, Islamic Republic of
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 80
- Registration Number
- NCT05644210
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.